Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025. Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced...
Insilico Medicine Nominates Preclinical Candidate of Inhalation Solution for ISM001-055, the First Generative AI IPF Drug
Insilico Medicine merges nebulizer device with AI-driven drug discovery; Potential advantages for the inhalation solution include a smaller effective dose, larger safety window and reduced side effects; As demonstrated in preclinical studies, the...